Physician profile
John R Powell
NPI 1699777029
$4,350.50
in general payments reported to CMS, 2019-2025
16 companies · $1,080 in 2025
The $1,080 reported for 2025 was more than what 95% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2021: $838 · 2022: $480 · 2023: $747 · 2024: $989 · 2025: $1,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,815.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,998.00 | 2021-2025 | Breztri, Airsupra, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $402.90 | 2019-2021 | |
| Grifols USA, LLC | $368.64 | 2022-2023 | Gamunex-C, Xembify |
| Abbott Laboratories | $298.41 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $220.53 | 2021-2024 | Wegovy |
| W. L. Gore & Associates, INC. | $138.24 | 2024 | Gore Cardioform Septal Occluder |
| Abbvie INC. | $126.55 | 2021 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.92 | 2025 | Jardiance |
| Esperion Therapeutics, INC. | $122.03 | 2024 | Nexletol, Nexlizet |
| Glaxosmithkline, LLC. | $111.88 | 2023 | |
| Axsome Therapeutics, INC. | $109.53 | 2025 | Auvelity |
| Gilead Sciences, INC. | $102.59 | 2024 | Descovy |
| Lilly USA, LLC | $59.63 | 2019-2023 | Mounjaro |
| Pfizer INC. | $21.56 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $21.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.